The FDA's new genAI-assisted scientific review technology, named Elsa, was officially adopted by the agency on 2 June.

The FDA’s tool—nicknamed Elsa—is designed to assist employees with everything from scientific reviews to basic operations. Originally, the FDA planned to launch by June 30, ...

The FDA will plan to focus Elsa’s scope on administrative tasks such as summarizing documents and data extraction. This is the right approach, according to Panna Sharma, CEO and president of ...

FDA claims victory with "Elsa" AI tool launch, but insiders call it half-baked Employees say FDA's Elsa launch prioritized optics over usability By Cal Jeffrey June 5, 2025, 13:39.

The FDA is using Elsa to accelerate clinical protocol reviews, shorten the time needed for scientific evaluations and identify high-priority inspection targets. The Food and Drug Administration ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. The FDA plans to roll out its new AI tool, called Elsa ...

The FDA launched a generative artificial intelligence (AI) tool, dubbed Elsa, designed to help employees such as scientific reviewers and investigators work more efficiently, the agency announced ...

Qualifying manufacturers will be able to submit some data while clinical trials are ongoing. Marty Makary is the commissioner ...

Elsa’s deployment comes ahead of schedule, with the rollout date initially slated for June 30. Leadership at the FDA has been keen to incorporate more AI tools across agency operations following ...

The FDA launched an artificial intelligence tool Monday dubbed Elsa, with Commissioner Marty Makary hyping the effort’s early debut “to modernize how the agency functions.” ...